Halozyme Therapeutics (HALO)
(Delayed Data from NSDQ)
$64.42 USD
+1.22 (1.93%)
Updated Aug 28, 2024 04:00 PM ET
After-Market: $64.96 +0.54 (0.84%) 7:36 PM ET
3-Hold of 5 3
B Value C Growth B Momentum C VGM
Earnings News For HALO
-
Halozyme's (HALO) Q2 Earnings & Sales Top Estimates, Stock Up
-
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Beat Estimates
-
Halozyme Therapeutics: Q2 Earnings Snapshot
-
HALOZYME REPORTS SECOND QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Up 8.7% Since Last Earnings Report: Can It Continue?
-
Halozyme's (HALO) Q1 Earnings Beat, Revenues Lag Estimates
-
Halozyme Therapeutics (HALO) Q1 Earnings Beat Estimates
-
Halozyme Therapeutics: Q1 Earnings Snapshot
-
HALOZYME REPORTS FIRST QUARTER 2024 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
-
Why Is Halozyme Therapeutics (HALO) Up 5.3% Since Last Earnings Report?
-
Halozyme (HALO) Q4 Earnings Match Estimates, Revenues Lag
-
Halozyme Therapeutics: Q4 Earnings Snapshot
-
Halozyme Therapeutics (HALO) Q4 Earnings Match Estimates
-
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
-
Why Is Halozyme Therapeutics (HALO) Up 2.8% Since Last Earnings Report?
-
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
-
Halozyme Therapeutics: Q3 Earnings Snapshot
-
Halozyme Therapeutics (HALO) Q3 Earnings Surpass Estimates
-
HALOZYME REPORTS THIRD QUARTER 2023 FINANCIAL AND OPERATING RESULTS
-
Halozyme Therapeutics (HALO) Down 3.8% Since Last Earnings Report: Can It Rebound?
-
Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised
-
Halozyme Therapeutics (HALO) Q2 Earnings and Revenues Top Estimates
-
Halozyme Therapeutics: Q2 Earnings Snapshot